公开(公告)号：US20250057837A1

公开(公告)日：2025-02-20

申请号：US18935760

申请日：2024-11-04

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Tianli Wang

IPC: A61K31/498 ,  A61K31/454 ,  A61K31/7056 ,  A61K31/7072 ,  A61P31/14 ,  G06F7/00 ,  G06F16/215 ,  G06F16/23 ,  G06F16/25

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20160074462A1

公开(公告)日：2016-03-17

申请号：US14849836

申请日：2015-09-10

Applicant: AbbVie Inc.

Inventor： Sandeep Dutta ,  Rajeev Menon ,  Akshanth Polepally ,  Tianli Wang

IPC: A61K38/07 ,  A23L1/29 ,  A61K31/427 ,  A61K31/513 ,  A61K38/05

CPC classification number: A61K38/07 ,  A23L33/30 ,  A23V2002/00 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/497 ,  A61K31/513 ,  A61K31/7056 ,  A61K38/05 ,  A61K2300/00

Abstract: This application features methods of treating HCV using Compound 1/r, Compound 2 and/or Compound 3.

Abstract translation: 本申请的特征在于使用化合物1 / r，化合物2和/或化合物3治疗HCV的方法。

公开(公告)号：US20240115650A1

公开(公告)日：2024-04-11

申请号：US18534967

申请日：2023-12-11

Applicant: ABBVIE INC.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang ,  Sven Mensing

IPC: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072 ,  A61K38/05

CPC classification number: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072 ,  A61K38/05

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220288153A1

公开(公告)日：2022-09-15

申请号：US17484287

申请日：2021-09-24

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang ,  Sven Mensing

IPC: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20150209403A1

公开(公告)日：2015-07-30

申请号：US14606369

申请日：2015-01-27

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Prajakta Badri ,  Daniel E. Cohen ,  Sandeep Dutta ,  Amit Khatri ,  Rajeev M. Menon ,  Thomas Podsadecki ,  Akshanth Polepally ,  Roger Trinh ,  Tianli Wang ,  Jiuhong Zha

IPC: A61K38/06 ,  A61K38/05 ,  A61K45/06 ,  A61K31/513

CPC classification number: A61K38/06 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/496 ,  A61K31/497 ,  A61K31/513 ,  A61K31/55 ,  A61K38/05 ,  A61K45/06 ,  C07K5/0804 ,  A61K2300/00

Abstract: This application features dose adjustment for drugs co-administered with Compound 1, Compound 2 and/or Compound 3.

Abstract translation: 本申请对与化合物1，化合物2和/或化合物3共同施用的药物具有剂量调整。

公开(公告)号：US11484534B2

公开(公告)日：2022-11-01

申请号：US15431906

申请日：2017-02-14

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Tianli Wang

IPC: A61K31/498 ,  A61K31/454 ,  A61K38/05 ,  A61K38/06

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20160317603A9

公开(公告)日：2016-11-03

申请号：US14676378

申请日：2015-04-01

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang

IPC: A61K38/06 ,  A61K38/05 ,  A61K31/7056 ,  A61K31/7072

CPC classification number: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20150283199A1

公开(公告)日：2015-10-08

申请号：US14676378

申请日：2015-04-01

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang

IPC: A61K38/06 ,  A61K38/05 ,  A61K31/7056 ,  A61K31/7072

CPC classification number: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明具有用于治疗HCV的无干扰素治疗。 优选地，治疗超过较短的治疗持续时间，例如不超过12周。 一方面，治疗包括给具有HCV感染的受试者施用至少两种直接作用的抗病毒剂和利巴韦林，其中所述治疗持续12周，并且不包括施用干扰素，并且所述至少两种直接作用的抗病毒剂包含 a）化合物1或其药学上可接受的盐和（b）化合物2或其药学上可接受的盐。

公开(公告)号：US20230385268A1

公开(公告)日：2023-11-30

申请号：US18232896

申请日：2023-08-11

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki ,  Tianli Wang

IPC: G06F16/23 ,  G06F7/00 ,  G06F16/215 ,  G06F16/25

CPC classification number: G06F16/2365 ,  G06F7/00 ,  G06F16/215 ,  G06F16/2379 ,  G06F16/252

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20190336565A1

公开(公告)日：2019-11-07

申请号：US16405029

申请日：2019-05-07

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang ,  Sven Mensing

IPC: A61K38/06 ,  A61K31/498 ,  A61K31/7072 ,  A61K38/05 ,  A61K31/454

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.